Raynier Devillier

Raynier Devillier

UNVERIFIED PROFILE

Are you Raynier Devillier?   Register this Author

Register author
Raynier Devillier

Raynier Devillier

Publications by authors named "Raynier Devillier"

Are you Raynier Devillier?   Register this Author

53Publications

2214Reads

20Profile Views

[Haploidentical hematopoietic stem cell transplant: How to choose the best donor? Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Bull Cancer 2019 Oct 2. Epub 2019 Oct 2.

Université Paris 6 Pierre-et-Marie-Curie, groupe hospitalier Pitié-Salpêtrière, centre d'immunologie et des maladies infectieuses (CIMI-Paris), service d'hématologie clinique, UPMC CR7, CNRS ERL8255, Inserm U1135, 75013 Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.07.011DOI Listing
October 2019

Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes.

Bone Marrow Transplant 2019 03 6;54(3):458-464. Epub 2018 Aug 6.

Shanghai Institute of Hematology, Department of Hematology, Blood and Marrow Transplantation Center, Collaborative Innovation Center of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 18F/OPD Bldg 197 Rui Jin Road II, 200025, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0283-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462832PMC
March 2019

Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years.

Bone Marrow Transplant 2018 09 9;53(9):1096-1104. Epub 2018 Mar 9.

Aix-Marseille Univ, INSERM, IRD, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM), Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0133-5DOI Listing
September 2018

Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide.

Biol Blood Marrow Transplant 2018 03 13;24(3):549-554. Epub 2017 Dec 13.

Department of Hematology, Institut Paoli-Calmettes, Marseille, France; Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR 7258, Marseille, France; Medical Faculty, Aix-Marseille University, UM 105, Marseille, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.11.042DOI Listing
March 2018

T-cell-replete haploidentical transplantation in acute myeloid leukemia.

Exp Hematol 2018 02 17;58:5-16. Epub 2017 Nov 17.

Department of Hematology, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University UM 105, Marseille, France; Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, CNRS UMR 7258, Marseille, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2017.11.001DOI Listing
February 2018

Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases.

Eur J Cancer 2017 08;81:138-141

Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Aix Marseille Univ, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, Marseille, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.023DOI Listing
August 2017

Manufacturing Natural Killer Cells as Medicinal Products.

Front Immunol 2016 15;7:504. Epub 2016 Nov 15.

CBT-1409: INSERM, Aix Marseille Univ, Institut Paoli-Calmettes, AP-HM, Marseille, France; CRCM: INSERM, CNRS, Aix Marseille Univ, Institut Paoli-Calmettes, CRCM, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2016.00504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108783PMC
November 2016

Epigenetically centered evolution in an example of myeloid malignancy.

Am J Hematol 2016 09 4;91(9):E361-2. Epub 2016 Jul 4.

Centre de Recherche en Cancérologie de Marseille, Laboratoire D'Oncologie Moléculaire, UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR725, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24450DOI Listing
September 2016

Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.

Biol Blood Marrow Transplant 2016 Jan 1;22(1):119-24. Epub 2015 Sep 1.

Transplant and Cellular Therapy Unit, Institut Paoli Calmettes, Marseille, France; Hematology Department, Institut Paoli Calmettes, Marseille, France; Transplant unit, Department of Hemato-oncology, Humanitas Cancer Center, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.08.029DOI Listing
January 2016

Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.

Am J Hematol 2015 Feb 19;90(2):E29-30. Epub 2014 Nov 19.

Hematology Department, Institut Paoli Calmettes, Marseille, France; Aix-Marseille University, Medecine Faculty, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23884DOI Listing
February 2015

Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.

Am J Hematol 2015 Jan 18;90(1):E22-4. Epub 2014 Oct 18.

Hematology Department, Institut Paoli Calmettes, Marseille, France; Aix-Marseille University, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23850DOI Listing
January 2015

Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.

Hematol Oncol 2014 Dec 3;32(4):187-91. Epub 2013 Dec 3.

Department of Hematology, Institut Paoli-Calmettes-Université de la Méditerranée, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2119DOI Listing
December 2014

Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies.

Haematologica 2014 Nov 1;99(11):1762-8. Epub 2014 Aug 1.

Département d'Hématologie, Institut Paoli Calmettes, Marseille, France Aix-Marseille University, Marseille, France Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.105981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222478PMC
November 2014

Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.

Biol Blood Marrow Transplant 2014 Oct 14;20(10):1560-5. Epub 2014 Jun 14.

Hematology Department, Transplantation Program, Institut Paoli Calmettes, Marseille, France; Aix-Marseille Université, Marseille, France; Inserm UMR 1068/Centre de Recherche en Cancérologie de Marseille, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.06.006DOI Listing
October 2014

Constitutive AKT activation in follicular lymphoma.

BMC Cancer 2014 Aug 5;14:565. Epub 2014 Aug 5.

Inserm, U1068, Centre de Recherche en Cancérologie de Marseille, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-14-565DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131060PMC
August 2014

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

Biol Blood Marrow Transplant 2014 Mar 4;20(3):370-4. Epub 2013 Dec 4.

Hematology Department, Transplantation Program, Institut Paoli Calmettes, Marseille, France; Aix-Marseille Université, Marseille, France; Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.11.030DOI Listing
March 2014

A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.

Am J Hematol 2014 Jan;89(1):83-7

Département d'Onco-Hématologie, Institut Paoli-Calmettes, Unité de Transplantation et de Thérapie Cellulaire, F-13273, Marseille, France; Aix-Marseille Université, F-13007, Marseille, France; Inserm UMR1068, Centre de Recherche en Cancérologie de Marseille (CRCM), F-13009, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23592DOI Listing
January 2014

Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.

Am J Hematol 2012 Jul 25;87(7):659-62. Epub 2012 Apr 25.

Centre de Recherche en Cancérologie de Marseille, Laboratoire d'Oncologie Moléculaire, UMR Inserm, Institut Paoli-Calmettes, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23211DOI Listing
July 2012

Myeloid malignancies: mutations, models and management.

BMC Cancer 2012 Jul 23;12:304. Epub 2012 Jul 23.

Centre de Recherche en Cancérologie de Marseille, Laboratoire d'Oncologie Moléculaire; UMR1068 Inserm, Institut Paoli-Calmettes, 27 Bd, Leï Roure, BP 30059, Marseille, 13273, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-12-304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418560PMC
July 2012

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

J Hematol Oncol 2012 Mar 21;5:12. Epub 2012 Mar 21.

Centre de Recherche en Cancérologie de Marseille, Laboratoire d'Oncologie Moléculaire, UMR1068 Inserm, Institut Paoli-Calmettes, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1756-8722-5-12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355025PMC
March 2012